Avantect Ovarian Cancer Test
Ovarian cancer remains one of the most challenging gynecologic malignancies due to its tendency to present with few or nonspecific symptoms in the early stages, leading to diagnosis at advanced disease with poor survival rates. The three major types of ovarian cancer include epithelial tumors (most common), germ cell tumors, and stromal tumors.
The Avantect Ovarian Cancer Test is a liquid biopsy assay that analyzes cell-free DNA (cfDNA) in blood using next-generation sequencing (NGS) with 5-hydroxymethylcytosine (5hmC) enrichment. The assay integrates genomic and epigenomic signals to provide a qualitative result reported as either “Abnormal signal detected” or “Abnormal signal not detected.”
The test has been validated in more than 300 patients, showing a sensitivity of about 78% and a specificity of up to 94%. This performance is better than traditional markers such as CA-125. The Avantect test may be especially helpful for women with a family history of ovarian cancer or genetic risk factors (such as BRCA1/2 mutations) as part of ongoing risk assessment and monitoring. Early detection of abnormal signals may enable timely imaging, biopsy, and clinical intervention, with the potential to improve patient outcomes in high-risk individuals.
- Supports early detection of ovarian cancer, especially in women at elevated risk (e.g., BRCA1/2 mutations, strong family history)
- Provides adjunctive information for risk assessment and triage for imaging or biopsy
- May facilitate preventive interventions or earlier treatment in high-risk individuals
Not detected (No abnormal signal)
Whole blood, EDTA.
Stability
- Ambient: 3 days
- Refrigerated: 7 days
- Frozen: unstable
- J Mol Diagn. 2024 Oct;26(10):888-896. [PMID: 39230538]
- Adv Clin Chem. 2020;97:13-71. [PMID: 32448432]
- Med Oncol. 2023 Aug 10;40(9):265. [PMID: 37561363]
- Crit Rev Oncol Hematol. 2024 Feb;194:104263. [PMID: 38218208]